EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV : Findings From an International Cohort

Brendan L Harney iD, Rachel Sacks-Davis, Daniela K van Santen, Ashleigh C Stewart, Gail V Matthews, Joanne M Carson, Marina B Klein, Karine Lacombe, Linda Wittkop, Dominque Salmon, Olivier Leleux, Laurence Merchadou und 9 weitere

Liver International · 2025

DOI: 10.1111/liv.16203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Brendan L Harney und 20 weiteren Autor:innen. Beteiligte Einrichtung: Disease Elimination Program, Burnet Institute, Melbourne, Australia. Hauptthemen laut MEDLINE: Antiviral Agents, HIV Infections, Treatment Failure, Hepacivirus. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Australian Department of Health, the Dutch Ministry of Health, Welfare and Sport.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Historically, hepatitis C virus (HCV) was difficult to treat among people with HIV. However, treatment with direct‐acting antivirals (DAAs) results in 90%–95% of people being cured. There is a need to understand why a proportion of people are not cured. We aimed to examine characteristics that may indicate an increased probability of unsuccessful DAA HCV treatment.

Methods

Data were from the International Collaboration on Hepatitis C Elimination in HIV Cohorts. People who commenced DAA HCV treatment between 2014 and 2019 were included. Unsuccessful treatment was defined as a positive HCV RNA test at a person's first RNA test at least 4 weeks (SVR4+) following the end of treatment. Multivariable mixed‐effects logistic regression was used to examine characteristics associated with unsuccessful treatment.

Results

Of 4468 people who commenced DAA treatment, 4098 (91.7%) had an SVR test 4+ weeks following the end of treatment, 207 (5%) of whom were unsuccessfully treated. Compared to a CD4+ cell count > 500 cells/mm 3 , cell counts < 200 (aOR 1.81, 95%CI 1.00–3.29) and between 200 and 349 (aOR 1.95, 95%CI 1.30–2.93) were associated with increased odds of unsuccessful treatment. Among 1921 people with data on injection drug use in the 12 months prior to treatment, there was some evidence that recent injection drug use was associated with increased odds of unsuccessful treatment; however, this was not statistically significant (aOR 1.67, 95%CI 0.99–2.82).

Conclusions

The overwhelming majority of people were successfully treated for HCV. Overall, 5% of those with an SVR4+ test were unsuccessfully treated; this was more likely among people with evidence of immunodeficiency and those who reported recently injecting drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHIV InfectionsTreatment FailureHepacivirusHumansMaleFemaleAdultMiddle AgedHepatitis C, ChronicSustained Virologic ResponseCD4 Lymphocyte CountLogistic ModelsRNA, ViralHepatitis CCoinfectionCohort Studies

Stichwörter der Autor:innen

HIVclinical researchdirect acting antiviralhepatitis Ctreatment

Substanzen

Antiviral AgentsRNA, Viral

Autor:innen und Institutionen

  • Disease Elimination Program, Burnet Institute, Melbourne, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Australia.
  • School of Population and Global Health, University of Melbourne, Melbourne, Australia.
  • Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
  • The Kirby Institute UNSW, Sydney, Australia.

ORCID-Profile: Brendan L Harney, Juan Berenguer

Förderung

  • National Health and Medical Research Council
  • Australian Department of Health
  • the Dutch Ministry of Health, Welfare and Sport
  • Centre for Infectious Disease Control of the National Institute for Public Health and the Environment
  • CIHR
  • CIHR Canadian HIV Trials Network
  • Fonds de recherche du Québec-Santé (FRQ-S): Réseau SIDA/maladies infectieuses
  • Gilead

Zitieren

APA

Harney, B. L., Sacks-Davis, R., van Santen, D. K., Stewart, A. C., Matthews, G. V., Carson, J. M., Klein, M. B., Lacombe, K., Wittkop, L., Salmon, D., Leleux, O., Merchadou, L., van der Valk, M., Smit, C., Prins, M., Boyd, A., Berenguer, J., Jarrin, I., Rauch, A., …, & Doyle, J. S. (2025). Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV : Findings From an International Cohort. Liver International. https://doi.org/10.1111/liv.16203

Vancouver

Harney BL, Sacks-Davis R, van Santen DK, Stewart AC, Matthews GV, Carson JM, et al. Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV : Findings From an International Cohort. Liver International. 2025. doi:10.1111/liv.16203

BibTeX
@article{Harney2025,
  author = {Harney, Brendan L and Sacks-Davis, Rachel and van Santen, Daniela K and Stewart, Ashleigh C and Matthews, Gail V and Carson, Joanne M and Klein, Marina B and Lacombe, Karine and Wittkop, Linda and Salmon, Dominque and Leleux, Olivier and Merchadou, Laurence and van der Valk, Marc and Smit, Colette and Prins, Maria and Boyd, Anders and Berenguer, Juan and Jarrin, Inmaculada and Rauch, Andri and Hellard, Margaret E and Doyle, Joseph S},
  title = {Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV : Findings From an International Cohort},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.16203}
}
Kostenlos starten →